Recombinant Human BLMH/Bleomycin Hydrolase Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 6200-CY

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
6200-CY-010
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

E. coli

Accession #

Q13867

Conjugate

Unconjugated

Applications

Enzyme Activity

View all BLMH/Bleomycin Hydrolase Proteins and Enzymes »

Product Specifications

Source

E. coli-derived human BLMH/Bleomycin Hydrolase protein
Ser2-Glu455, with an N-terminal Met and 6-His tag

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Met

Predicted Molecular Mass

53 kDa

SDS-PAGE

45-50 kDa, reducing conditions

Activity

Measured by its ability to hydrolyze Met-AMC.
The specific activity is >500 pmol/min/μg, as measured under the described conditions.

Formulation, Preparation and Storage

6200-CY
Formulation Supplied as a 0.2 μm filtered solution in Tris, NaCl, Glycerol and DTT.
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -70 °C as supplied.
  • 3 months, -70 °C under sterile conditions after opening.

Background: BLMH/Bleomycin Hydrolase

Bleomycin Hydrolase (BLMH) is a cysteine peptidase of the papain superfamily. It is named for its ability to hydrolyze the antitumor agent bleomycin and inactivate it (1). It has a papain-like catalytic triad (Cys-His-Asp) with optimum activity at neutral pH. In mammals it is expressed ubiquitously in all types of tissues and its expression is up‑regulated in many tumors. It is present in the cytoplasm as homohexameric protein of approximately 300 kDa. In addition to its aminopeptidase activity, it has homocysteine-thiolactonase activity. The normal physiological function of BLMH is not clear. BLMH inactivates bleomycin, a glycopeptide anticancer agent, by deaminating it (2). BLMH has been suggested to play a role in the generation of MHC class I-presented peptides (3, 4). Diminished BLMH activity may contribute to the pathology of Alzheimer’s disease (AD) (5, 6). It is inhibited by cysteine protease inhibitors such as N-ethylmaleimide, iodoacetamide, para‑hydroxymercuribenzoate, and E-64.

References

  1. Joshua-Tor, L. and S. A. Johnson (2004) in Handbook of Proteolytic Enzymes, Barrett, A. J. et al. eds. pp. 1197.
  2. Schwartz, D. R. et al. (1999) Proc. Natl. Acad. Sci. USA, 96:4680.
  3. Kim, E. et al. (2009) J. Immunol. 183:7379.
  4. Towne, C. F. et al. (2007) J. Immunol. 178:6923.
  5. Suszynska, J. et al. (2010) J. Alzheimers Dis. 19:1177.
  6. Lefterov, I. M. et al. (2000) FASEB J. 14:1837.

Alternate Names

BMH

Entrez Gene IDs

642 (Human)

Gene Symbol

BLMH

UniProt

Q13867

Additional BLMH/Bleomycin Hydrolase Products

Product Documents for Recombinant Human BLMH/Bleomycin Hydrolase Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human BLMH/Bleomycin Hydrolase Protein, CF

Coomassie is a registered trademark of Imperial Chemical Industries Ltd.

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.